• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Thromboelastography (TEG): A Point-Of-Care Tool to Assess Coagulopathy During PPH

image_pdfFavoriteLoadingFavorite

PURPOSE:

  • Thromboelastography (TEG) can determine whether a patient has impaired coagulation  
  • A thin wire is placed in a blood sample and clot formation rate, strength, stability, retraction and lysis can be measured using computational modeling
  • Point-of-care TEG analyzers are available that can readily measure clot changes in strength and elasticity and are used by anesthesiology and surgery services when coagulation status is urgently required
  • Rigouzzo et al. (Anesthesia & Analgesia, 2020) assessed the accuracy of TEG vs standard coagulopathy lab testing during postpartum hemorrhage

METHODS:

  • Retrospective observational cohort study
  • Participants
    • Women with PPH >500 mL who were bleeding sufficiently to require coagulation assessment
  • Coagulopathy definition (‘Gold Standard’)
    • Hypofibrinogenemia ≤2 g/L
    • Thrombocytopenia ≤80,000/mm3
    • Prothrombin ratio (PR) ≤50% or aPTT ratio ≥1.5)
  • TEG parameters
    • Kaolin assays: Kaolin-maximum amplitude (K-MA) | Kaolin-maximum rate of thrombus generation using G (K-MRTGG)
    • Functional fibrinogen assays: Functional fibrinogen -maximum amplitude (FF-MA) | Functional fibrinogen-maximum rate of thrombus generation using G (FF-MRTGG)
  • Primary outcome
    • To Compare predictive accuracy of TEG parameters vs standard lab parameters
  • Secondary outcomes
    • To compare the time delay between TEG amplitude parameters vs velocity curve-derived parameters
    • To evaluate the accuracy of TEG parameters to predict severe hemorrhage based on blood loss

RESULTS:

  • 98 patients were included
    • All parameters had excellent predictive performance
  • Kaolin assay
    • No significant difference between the amplitude assay (K-MA) vs velocity assay for prediction of hypofibrinogenemia and/or thrombocytopenia (AUC, 0.970 vs 0.981)
  • Functional fibrinogen assay
    • No significant difference between amplitude assay (FF-MA) vs velocity assay (FF-MRTGG) for the prediction of hypofibrinogenemia (AUC, 0.988 vs 0.974)
  • Time to obtain results were shorter with the velocity vs the amplitude assays
    • K-MRTGG: 7.7 minutes vs K-MA: 24.7 minutes (P < .001)
    • FF-MRTGG: 2.7 minutes versus FF-MA: 14.0 minutes (P < .001)
  • PPH prediction: TEG parameters were significantly predictive for severe PPH >2500 mL, transfusion of >4 RBC units, and transfusion of FFP
  • TEG did not perform as well for the prediction of PR / aPTT (AUC 0.651)

CONCLUSION:

  • TEG can reliably detect hypofibrinogenemia and/or thrombocytopenia during PPH
  • Using velocity-based parameters, results can be obtained in minutes, vs lab testing which may require transport, analysis and reporting back to the OR
  • The authors state

…when coagulation assessment is indicated, TEG parameters rapidly predict hypofibrinogenemia and/or thrombocytopenia during PPH

This approach may help physicians achieve rapid diagnosis and treatment of clotting disorders during evolving PPH 

Learn More – Primary Sources:

Assessment of Coagulation by Thromboelastography During Ongoing Postpartum Hemorrhage: A Retrospective Cohort Analysis

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

Try it Free  »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Postpartum Hemorrhage – Medications to Treat Uterine Atony 
Postpartum Hemorrhage Prophylaxis – Is IM or IV Route Better?
What are the Possible Causes of a PPH that is Unresponsive to First Line Uterotonics?
Latest Cochrane Review: What is the Most Effective Prophylactic Treatment for Postpartum Hemorrhage?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site